A top 1% fund manager with 30 years of experience X A patent attorney specializing in pharmaceuticals and biotechnology
The top 5 domestic big biotech companies that they discovered will grow tenfold in five years.

"The 2025 Tenbagger Opportunity Lies in Korean Bio."
Why You Should Invest in Companies That Will Grow Tenfold in Five Years

The bio market, which has gone through several upheavals, is recently emerging with a new look.
Now that biotechnology is starting to bear fruit, the biotech stock market holds tremendous potential.
The time has finally come to focus on companies with the potential to grow into big biotechs by developing blockbuster new drugs in areas with significant unmet needs.
The time has come to invest in biotech companies that will remain unshaken by the tremendous volatility currently sweeping the investment market.

"Invest in Biotech Companies That Will Grow Tenfold in Five Years" is a book that provides insightful analysis of five domestic companies that are poised to grow steadily into future big biotech companies even in a rapidly changing market.
We selected companies that possess sufficient competitiveness from a comprehensive perspective, including biotechnology trends, global technological competitiveness (technology export performance), clinical data competitiveness, cash reserves, and reliability, and have secured numerous pipelines with high blockbuster potential.
These are companies whose main pipelines have entered the Phase 3 clinical trial stage or are in the Phase 2 clinical trial stage, and thus visible clinical results are expected in the near future.

Now is the time for domestic big biotech companies.
Only an interest in and study of the bio sector will allow you to overcome the countless volatility and doubts of the next decade of bio-exploration and lead you to a treasure island filled with big biotechs.

The core message of this book is that we must now prepare to welcome domestic big biotech companies.
In the process of establishing the mechanism by which biotechnology, which had been left in a gray area and unstudied for a long time, grows into a big biotech, the importance of blockbusters was recognized once again, which was a very significant gain.
In short, blockbusters are like a gateway that must be passed through to advance to big biotech.
All big biotechs are companies that have created blockbusters, boldly reinvested the large amounts of funds generated from these blockbusters into R&D, and ultimately secured multiple blockbusters.
It is no exaggeration to say that blockbusters are soon to become big biotechs.
---From the "Prologue"

The paths taken by companies that have grown into big biotech companies are all different, but they all eventually converge in one place: 'Blockbuster.'
Although each company has its own unique technology, target indications, management strategy, and financial status, the story of how they grew into big biotech companies by developing blockbusters remains the same.
A blockbuster is a new drug that generates sales of more than $1 billion.
To become a blockbuster, a drug must demonstrate exceptional efficacy in an area with significant unmet need.
That is, first-in-class or best-in-class drugs are more likely to become blockbusters.

---From "Big Biotech and Blockbusters"

Domestic biotech companies are also dreaming of becoming big biotechs, each following their own path in their own way.
We never imagined that domestic new drug development companies would grow into big biotech companies.
I had a vague notion that Big Biotech was a huge mountain that could not be overcome, and I never even thought about looking at it directly.
Now is the time to analyze what Big Biotech is and the process through which it grew.
This is because Yuhan Corporation's Reclaza has been approved as a new drug, increasing the likelihood that it will grow into a blockbuster.
Moreover, in 2025, the year when we begin anew, many major domestic bio companies are scheduled to announce the results of their global phase 3 clinical trials and obtain new drug approvals.
Now is the time to dream of becoming a domestic big biotech company and prepare for investment in it.
---From "Big Biotech and Blockbusters"

On the surface, it may seem like success, but inside, there are just as many failures as successes.
Dealing with failure is our destiny as an R&D company, and developing an options portfolio is the best way to deal with uncertainty.
There is no such thing as good or bad clinical data.
Data is just data.
Based on this data, it is more important to decide which options to invest in and which ones to forgo.

---From "Daiichi Sankyo, a brand that has become a renowned ADC brand by fusing retro and trends"

Now is the time for domestic investors to prepare for investment in big biotech companies.
We should pay attention to companies that can develop blockbusters like Reclaza, which have outstanding efficacy in areas with high unmet needs.
As seen through the cases of the three global big biotech companies, companies that secure blockbusters are more likely to use these resources as a foundation for active R&D activities and grow into big biotechs with multiple blockbusters.
Blockbusters are the gateway to big biotech.
Starting with the launch of the first global anticancer drug, Reclaza, domestic bio companies are expected to launch many blockbusters in the future.
---From the "Epilogue"

Ultimately, the key is what it takes to become a blockbuster.
Companies with pipelines that meet these criteria are the ones we should invest in.
We should focus our attention on companies that have demonstrated first-in-class or best-in-class clinical performance in diseases with significant unmet needs but no viable treatments.
In other words, in the phase 2 clinical trial stage, which verifies efficacy for diseases with high unmet needs, the statistical significance of the primary efficacy evaluation indicator must be satisfied to a significant degree.
If these conditions are met, it is a company worth investing in.

---From the "Epilogue"